Patent US5876730A successfully refreshed from Google Patents.
US5876730A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Heparin-binding growth factor (HBGF) polypeptides
Assignee: Childrens Hospital Research Foundation
•
Filing: 1997-08-07
•
Granted: 1999-03-02
•
Expires: 2017-08-07
Abstract
Abstract Substantially pure heparin-binding growth factor polypeptides (HBGFs), nucleic acids encoding the HBGFs and antibodies which bind to the HBGFs of the invention are provided. The HBGF polypeptides are useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing. HBGF is related to Connective Tissue Growth Factor (CTGF).
Inventors
- 👤 David R. Brigstock
- 👤 Paul A. Harding
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:31
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/475; A; A61; A61P; A61P15/00; A61P17/00; A61P17/02; A61P19/00; A61P21/00; A61P43/00; A61P9/00; A61P9/10; C07K16/00; C07K16/18; C07K16/22; C07K16/24; A61K; A61K38/00; C07K2317/00; C07K2317/30; C07K2317/34; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/85; Y10S930/00; Y10S930/01; Y10S930/12
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
52 words
A substantially pure polypeptide characterized as: a) having an amino acid sequence corresponding to the carboxy terminal amino acids of a connective tissue growth factor (CTGF) protein; b) binding to heparin and being eluted from heparin with about 0.8M salt; and c) having a molecular weight of about 10-kDa by reducing SDS-PAGE.
Claim 2
Dependent Claim
52 words
A substantially pure polypeptide characterized as: a) having an amino acid sequence corresponding to the carboxy terminal amino acids of a connective tissue growth factor (CTGF) protein; b) binding to heparin and being eluted from heparin with about 0.8M salt; and c) having a molecular weight of about 10-kDa by reducing SDS-PAGE.
Claim 3
Dependent Claim
24 words
The polypeptide of claim 1, wherein the polypeptide has an amino acid sequence beginning at amino acid residue 247 from the N-terminus of CTGF.
Claim 4
Dependent Claim
24 words
The polypeptide of claim 1, wherein the polypeptide has an amino acid sequence beginning at amino acid residue 248 from the N-terminus of CTGF.
Claim 5
Dependent Claim
21 words
An isolated polynucleotide sequence encoding a polypeptide having an amino acid sequence as in any of claims 1, 2 or 3.
Claim 6
Dependent Claim
11 words
A recombinant expression vector which contains the polynucleotide of claim 4.
Claim 7
Dependent Claim
11 words
A host cell which contains the expression vector of claim 5.
Claim 8
Dependent Claim
11 words
The host cell of claim 6, which is a prokaryote cell.
Claim 9
Dependent Claim
11 words
The host cell of claim 6, which is an eukaryote cell.
Claim 10
Dependent Claim
19 words
A pharmaceutical composition comprising a therapeutically effective amount of the HBGF of claim 1 in a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
US5408040A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-03-01 | 2002-08-31 | 2003-03-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-03-01 | 2006-08-31 | 2007-03-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-03-01 | 2010-08-31 | 2011-03-02 | $7700.00 | Window Closed / Lapsed |